NGeneBio Co., Ltd. (KOSDAQ: 354200)
South Korea
· Delayed Price · Currency is KRW 3,175.00
-225.00 (-6.62%)
Oct 11, 2024, 9:00 AM KST
NGeneBio Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -13,284 | -12,769 | -9,785 | -8,431 |
| Depreciation & Amortization | 1,756 | 1,344 | 1,274 | 1,030 |
| Loss (Gain) From Sale of Assets | -0.56 | 20.85 | 0.99 | 11.15 |
| Asset Writedown & Restructuring Costs | 94.28 | 97.62 | 34.1 | 24.56 |
| Loss (Gain) From Sale of Investments | 508.1 | 526.16 | 144.52 | - |
| Loss (Gain) on Equity Investments | - | - | - | -199.05 |
| Stock-Based Compensation | 82.68 | 0.2 | 241.31 | 501.98 |
| Provision & Write-off of Bad Debts | 10.19 | 172.03 | - | - |
| Other Operating Activities | 626.58 | 1,600 | 2,445 | 563.07 |
| Change in Accounts Receivable | -1,058 | 166.34 | 456.28 | -1,134 |
| Change in Inventory | 317.09 | -116.18 | -1,893 | 21.03 |
| Change in Accounts Payable | -16.08 | 93.57 | -103.67 | -218.25 |
| Change in Unearned Revenue | -9.17 | -20.17 | 1.83 | -16.22 |
| Change in Other Net Operating Assets | 105.45 | -282.74 | -636.23 | 323.61 |
| Operating Cash Flow | -10,868 | -9,167 | -7,820 | -7,523 |
| Capital Expenditures | -768.67 | -386.37 | -1,029 | -3,023 |
| Cash Acquisitions | -7,530 | - | - | 20.72 |
| Sale (Purchase) of Intangibles | -143.21 | -441.76 | -196.22 | -349.22 |
| Investment in Securities | -1,086 | 4,885 | 1,918 | -13,348 |
| Other Investing Activities | -50.89 | 74.57 | -107.76 | -679.42 |
| Investing Cash Flow | -9,579 | 4,131 | 585.23 | -17,378 |
| Short-Term Debt Issued | - | - | - | 1,100 |
| Long-Term Debt Issued | - | - | 19,866 | 500 |
| Total Debt Issued | 5,604 | - | 19,866 | 1,600 |
| Short-Term Debt Repaid | - | -500 | -3,600 | - |
| Long-Term Debt Repaid | - | -327.9 | -1,116 | -162.54 |
| Total Debt Repaid | -10,300 | -827.9 | -4,716 | -162.54 |
| Net Debt Issued (Repaid) | -4,695 | -827.9 | 15,151 | 1,437 |
| Issuance of Common Stock | - | 220.35 | 516.93 | 457.15 |
| Other Financing Activities | 2,053 | - | 130 | - |
| Financing Cash Flow | -2,643 | -607.55 | 15,797 | 1,895 |
| Foreign Exchange Rate Adjustments | 12.32 | 20.72 | 38.95 | 0.11 |
| Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | - |
| Net Cash Flow | -23,078 | -5,623 | 8,601 | -23,006 |
| Free Cash Flow | -11,637 | -9,553 | -8,849 | -10,546 |
| Free Cash Flow Margin | -233.27% | -219.57% | -80.32% | -147.22% |
| Free Cash Flow Per Share | -906.70 | -753.13 | -709.15 | -852.68 |
| Cash Interest Paid | 103.45 | 81.53 | 146.88 | 141.93 |
| Cash Income Tax Paid | - | 36.48 | 96.12 | 20.01 |
| Levered Free Cash Flow | -14,567 | -10,880 | 5,799 | - |
| Unlevered Free Cash Flow | -13,462 | -9,767 | 6,215 | - |
| Change in Net Working Capital | 5,903 | 1,840 | -11,401 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.